DOCSLIB.ORG

Interactions Antimicrobial Action Pharmacokinetics Uses And

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Interactions Antimicrobial Action Pharmacokinetics Uses And 585 Hypochlorhydria, which may be present in patients with also required with calcium -channel blockers, which may membranes for I to 4 weeks after the drug is stopped. Small AIDS, can reduce absorption of itraconazole. In this case increase the risk of congestive heart failure if given together, amounts are distributed into breast milk. absorption may be improved by giving itraconazole with an and nisoldipine in particular is considered contra-indicated. Itraconazole is metabolised in the liver mainly by acidic drink, such as a cola beverage. Use with the statins is also best avoided because of the risk of cytochrome P450 isoenzyme CYP3A4. The major metabo­ muscle damage. lite, hydroxyitraconazole, has antifungal activity compar­ Breast feeding. Licensed product information does not Reviews of drug interactions vvith azole antifungals. able with that of itraconazole. Itraconazole is also excreted recommend breast feeding while receiving itraconazole Baciewicz FA. Ketoconazole and lluconazole drug as inactive metabolites in the bile or urine; 3 to 18% is although only small amounts of itraconazole are distribu­ Intern Med 1993; 153: 1970-6. excreted in the faeces as unchanged drug. Small amounts 2. Lomae.;;tro BM, on drug interactions with awle ted into breast milk. are eliminated in the stratum corneum and hair. Itracon­ antifungal agents. Ann 1998; 32: 915-28. 3. Venkatakrishnan K, et a!. Effects of the antifungal on oxidative azole is not removed by dialysis. Porphyria. The Drug Database for Acute Porphyria, com­ drug metabolism: clinical relevance. Clin 2000; 38: 111- The elimination half-life after a single 100-mg dose has piled by the Norwegian Porphyria Centre (NAPOS) and 80. been reported as 20 hours, increasing to 30 to 40 hours with the Porphyria Centre Sweden, classifies itraconazole as continued use. probably porphyrinogenic; it should be prescribed only for Immunosuppressants. Fatal hepatitis occurred in a 68- compelling reasons and precautions should be considered year-old woman 1 after 2 months of use of itraconazole P.r�p�r<:Jii<:J':lS. in all patients.1 and leflunomide. The authors suggested that the combined hepatotoxicity of both drugs might have accounted for ProprietaryPreparations (details are given in Volume B) l. The Drug Database for Acute Porphyria. Available at http://www. this. drugs-porphyria.org (accessed 14/10/ll) Single-ingredient Preparations. Arg.: Itrac; Micotenk; Nitridazol; l. A, et al. Fatal hepatitis with leflunomide and itraconazole. Am 1 Panastat; Salimidin; Sporanox; Austral.: Sporanox; Austria: 113: 352-3 . Itrabene; Sporanox; Belg.: Sporanox; Braz.: Estiranox; Fungo­ Interactions nax; ltraconolt; Itracotan; Itrahexal; Itralex; Itraspor; Itrazol; Enzyme-inducing drugs such as carbamazepine, isoniazid, Metal ions. Didanosine in a formulation containing alu­ Neo Itrax; Sporanox; Spozol; Traconal; Tracozont; Tratzol; nevirapine, phenobarbital, phenytoin, rifabutin, rifampicin, minium and magnesium ion buffering agents could reduce Traxonol; Canad.: Sporanox; Chile: Itodal; Sporanox; Teramic; or St John's wort may decrease plasma concentrations of the absorption of itraconazole due to the resultant increase China: Mei Fu Sporanox (J!Ji&f=t!i): Yi Qi Kang itraconazole sufficiently to reduce its efficacy. Conversely, in gastric pH. 1 �); Cz. : Cladostad;(9iem): Prokanazol; Sporanox; Denm.: Itrastad; (§Nid­;;;; dazol; Sporanox; Sporanox; Sporanox; Itracolt; enzyme inhibitors such as clarithromycin, erythromycin, I. Moreno F, et al. Itraconazole-didanosine excipient interaction. lAMA Fin.: Fr.: Ger.: 269: Itraconbeta; Itradenn; Sempera; Slro:.; Assosept-S; Bevona­ HIV-protease inhibitors, including ritonavir-boosted HIV­ 199 3; 1508. Gr.: zole; Brovicton; Deratil; Etrel; Fansidol; Flunol; Fungonazol; protease inhibitors, may increase plasma concentrations of Fungospor; Idranox; Inrozol; Isoflon; Itrabest; Itracon; Itraco­ itraconazole. Use of drugs that reduce stomach acidity, such Antimicrobial Action nal; Itralfa; Itraproton; Itraspor; Itraviron; Itrazol; Laverio; Lor­ as antimuscarinics, antacids, proton pump inhibitors, and Itraconazole is a triazole antifungal drug that in sensitive enzo!; Mesmor; Micronazol; Mycodrox; Neo-Candimyk; Promi­ histamine H -receptor antagonists, may reduce the 2 fungi inhibits cytochrome P450-dependent enzymes nox; Soprazon; Sporanox; Sporizole; Stas; Sterginox; Zetilox; absorption of itraconazole. resulting in impairment of ergosterol synthesis in fungal Hong Kong: Aranox; Inox; Itracon; Itranstad; Quali-itrazole; Like other triazole antifungals, itraconazole is a potent Sporacidt; Sporanox; Cladostad; Itraconep; Itragen; cell membranes. It has a slightly wider spectrum of activity Hung.: inhibitor of the cytochrome P450 isoenzyme CYP3A4, and Omicral; Orungal; India: Biospore; Candistat; Canditral; Ful­ than ketoconazole. It is active against Aspergillus spp., may increase plasma concentrations of other drugs reliant cover; Fungicap; Itaspor; Itra; Itracan; Itrazen; Itrole; Indon.: Blastomyces dermatitidis, Candidaspp., Coccidioides immitis, upon it for their metabolism. This increases the risk of Forcanox; Fungitrazol; Furolnokt; Itzol; Mycotrazol; Nufatrac; Cryptococcus neoformans, Epidermophytonspp., Histoplasma adverse effects and such combinations should be given with Petrazole; Sporacid; Sporanox; Sporax; Spyrocon; Trachon; Tra­ capsulatum, Malassezia fu rfu r, Microsporum spp., Paracocci­ caution and careful monitoring, if at all. Drugs so affected cor; Unitrac; Zitrazolt; Irl.: Sporanox; Israel: Itranol; Sporanox; dioides brasiliensis, Sporothrix schenckii, and Trichophyton spp. may include: Ital. : Sporanox; Tranizolo; Trazer; Triasporin; Jpn: Itrizole; Itraconazole also has son1e antiprotozoal activity against antiarrhythmics such as disopyramide, dofetilide and Malaysia: Canditral; Inox; Itracon; Sporanox; Unitrac; Mex.: • Leishmania spp. Carexant; Conamed; Congox; Derusil; Ergospharmat; Fitocyd; quinidine Acquired resistance to itraconazole is rare but ketocon­ Fuzoltec; Imazolt; Iqcona; Isoporum; Isox; Itracosid; Itranax; antidepressants such as reboxetine • azole�resistant strains of Candida albicans have been found to Lozartil; Rixtal; Seritral; Silicsan; Sinozol; Solmavin; Sporanox; antiepileptics such as carbamazepine (which in turn • be cross resistant to itraconazole. Steitraz; Trax; Z-Fin; Zitriasol; Zolken; Zotril; Neth.: Trisporal; decreases the concentration of the antifungal, see above) Norw.: Sporanox; NZ: Itcozol; Itrazole; Sporanox; Philipp.: antihistamines such as astemizole, mizolastine, and • Microbiological interactions. Synergistic antifungal effects In ox; Sporanox; Pol. : ItraGen; ItraMerck; Orungal; Trioxal; terfenadine were seen in vitro with terbinafine and itraconazole against Port.: Fungizol; Itracic; Sporanox; Unisens; Rus.: Canditral antimalarials such as halofantrine (KaH,[{JIT}Jarr); Irunine (11pyHHH); Itramicol (UrpaM.llKOJI); Itrazol • strains of Candida albicans1 and Scedosporium prolzficans. 2 antimigraine drugs such as dihydroergotamine, ergo­ (Urpa3oJI); Miconihol (MHKOHHXOJI); Orungal (OpyHrarr); Orun­ • For effects on the antifungal activity of azoles when given metrine, ergotamine, methylergometrine, and eletriptan gamin (OpyHraMrrH); Orunit (OpyHHT); Rumycoz (PyMHK03); with amphotericin B, see p. 572.3. Teknazol (TeKH<l3orr); Adco-Sporozole; Sporanox; Tris­ • the antimycobacterial rifabutin (which again also S.Afr. : decreases antifungal concentrations) l. Barchiesi F, et al. In vitro activities of terbinafine in combination with poral; Singapore: Canditral; Hitrazole; Sporanox; Unitrac; fluconazole and itraconazole against isolates of Candida albkans with Spain: Canadiol; Hongoseril; Oromict; Sporanox; Swed.: antineop/astics such as busulfan, docetaxel, trimetrexate, reduced su�ceptibility to azoles. Antimicrob Agents Chemother 1997; 41: • Sporanox; Gosegyne G; Itraderm; Sporanox; Can­ and the vinca alkaloids 1812-14. Switz.: Thai.: antipsychotics such as pimozide and sertindole 2. Meletiadis J, et al. In vitro interaction of terhinaline with itrawnawle ditralt; Iconat; Itra; Itracon; Itrasix; Itrazole; Norspor; Spazol; • Sporal; Sporlabt; Spornar; Funit; Itraspor; Sporanox; anxio/ytics and sedatives such as buspirone Antimicrob Agents Turk.: • Sporex; UK: Sporanox; Ukr.: Funit (<llyHHT); Itracon (lfrpaKOH); benzodiazepines such as alprazolam, brotizolam, diaze­ • ltral (11Tp''-'); Orunzol (OpyH3on)t Sporagal (Cnoparan); Trioxal pam, rnidazolam, and triazolam Resistance. For a discussion of increasing resistance of (TpnoKcaJI)t; USA: Onmel; Sporanox; Venez.: Fungosin; calcium-channel blockers such as bepridil, verapamil, and : • Candida spp. to azoles, see under Antimicrobial Action of Sporanox. the dihydropyridines felodipine, nifedipine, and nisoldi­ Fluconazole, p. 580.2. Decreased susceptibility to itracon­ pine (see also below) Mex. : Gitrasek; Sepia; Sporasec; azole and cross-resistance to fluconazole has been reported Multi-ingredient Preparations. some corticosteroids such as budesonide, dexamethasone, Venez. : Sporasec. • in C. albicans isolated from patients with AIDS given long­ fluticasone and methylprednisolone term prophylaxis with itraconazole.1 Aspergillus fu migatus the coumarin anticoagulant warfarin • resistant to hraconazole has also been seen.2•3 the gastrointestinal prokinetic cisapride • l. Goldman M, et a!. Does long-term itraconazole prophylaxis result in in Ketoconazole (BAN, USAN, r/NN) • HIV-protease inhibitors such as indinavir, ritonavir, and vitro azoic resistance
Load more

Recommended publications
  • The Evaluation of Drug Regulation - Economic Approaches Into the Valuation and Evaluation of the Drug Regulatory Framework
    The Evaluation of Drug Regulation - Economic approaches into the valuation and evaluation of the drug regulatory framework Jacoline Bouvy The evaluation of drug regulation – Economic approaches into the valuation and evaluation of the drug regulatory framework Bouvy, JC. ISBN 000000 Author Jacoline Bouvy Cover photo Bigstock.com Printed by Drukkerij Mostert en Van Onderen! The evaluation of drug regulation – Economic approaches into the valuation and evaluation of the drug regulatory framework Evaluatie van geneesmiddelenregulering – Economische toepassingen in de waardering en evaluatie van het regulatoire geneesmiddelensysteem (met een samenvatting in het Nederlands) Proefschrift ter verkrijging van de graad van doctor aan de Universiteit Utrecht op gezag van de rector magnificus, prof.dr. G.J. van der Zwaan, ingevolge het besluit van het college voor promoties in het openbaar te verdedigen op woensdag 23 januari 2013 des middags te 12.45 uur door Jacoline Catharina Bouvy geboren op 27 maart 1985 te Rotterdam Promotor: Prof. dr. H. Schellekens Co-promotor: Dr. M.A. Koopmanschap The studies presented in this thesis were performed in the context of the Escher project (T6- 202), a project of the Dutch Top Institute Pharma. ‘It is our choices, Harry, that show what we truly are, far more than our abilities.’ Albus Dumbledore (In J.K. Rowling’s Harry Potter and the Chamber of Secrets) Glossary ADR Adverse drug reaction CBG-MEB Dutch Medicines Evaluation Board CKD Chronic Kidney Disease DCE Discrete Choice Experiment DHPC Direct Healthcare
    [Show full text]
  • Clinical and Biochemical Characteristics and Genotype – Phenotype Correlation in Finnish Variegate Porphyria Patients
    European Journal of Human Genetics (2002) 10, 649 – 657 ª 2002 Nature Publishing Group All rights reserved 1018 – 4813/02 $25.00 www.nature.com/ejhg ARTICLE Clinical and biochemical characteristics and genotype – phenotype correlation in Finnish variegate porphyria patients Mikael von und zu Fraunberg*,1, Kaisa Timonen2, Pertti Mustajoki1 and Raili Kauppinen1 1Department of Medicine, Division of Endocrinology, University Central Hospital of Helsinki, Biomedicum Helsinki, Helsinki, Finland; 2Department of Dermatology, University Central Hospital of Helsinki, Biomedicum Helsinki, Helsinki, Finland Variegate porphyria (VP) is an inherited metabolic disease resulting from the partial deficiency of protoporphyrinogen oxidase, the penultimate enzyme in the heme biosynthetic pathway. We have evaluated the clinical and biochemical outcome of 103 Finnish VP patients diagnosed between 1966 and 2001. Fifty-two per cent of patients had experienced clinical symptoms: 40% had photosensitivity, 27% acute attacks and 14% both manifestations. The proportion of patients with acute attacks has decreased dramatically from 38 to 14% in patients diagnosed before and after 1980, whereas the prevalence of skin symptoms had decreased only subtly from 45 to 34%. We have studied the correlation between PPOX genotype and clinical outcome of 90 patients with the three most common Finnish mutations I12T, R152C and 338G?C. The patients with the I12T mutation experienced no photosensitivity and acute attacks were rare (8%). Therefore, the occurrence of photosensitivity was lower in the I12T group compared to the R152C group (P=0.001), whereas no significant differences between the R152C and 338G?C groups could be observed. Biochemical abnormalities were significantly milder suggesting a milder form of the disease in patients with the I12T mutation.
    [Show full text]
  • IS IT AIP Symptoms Checker Summary
    Acute Intermittent Porphyria: Symptoms, Triggers, and Other Factors Common symptoms of acute intermittent porphyria (AIP) AIP can cause many different symptoms that tend to come and go. When someone with AIP has symptoms, the episode is called an AIP attack. A person may have certain symptoms during one attack but different symptoms during another attack. Severe abdominal pain • Severe abdominal pain is the most common symptom of AIP. More than 85% of people have abdominal pain during AIP attacks. • The pain often lasts for hours or days. • The pain tends to begin slowly and become worse. • The pain tends to be all over and not in one small area. • The pain may start in the chest or back and move to the abdomen. • Pain medicines such as Advil® (ibuprofen) or Tylenol® (acetaminophen) usually don’t help much. This is because the pain is caused by nerves. Nausea or vomiting • Nausea or vomiting is common during AIP attacks. • People with AIP often have nausea or vomiting along with abdominal pain. Constipation • Constipation is common during AIP attacks. • Loss of bladder control may go along with constipation. Dark or reddish urine • Urine that turns reddish or dark over time when exposed to light and air is common during AIP attacks. • The change in urine color is due to certain chemicals in the urine during AIP attacks. Muscle weakness • Muscle weakness is common during AIP attacks. • Muscle weakness usually begins in the arms and often in the shoulders. 1 Common symptoms of AIP (cont.) Pain in the arms, legs, back, chest, neck, or head • Abdominal pain is the most common symptom of AIP.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen Et Al
    USOO8603526B2 (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen et al. (45) Date of Patent: Dec. 10, 2013 (54) PHARMACEUTICAL COMPOSITIONS 2008. O152595 A1 6/2008 Emigh et al. RESISTANT TO ABUSE 2008. O166407 A1 7/2008 Shalaby et al. 2008/0299.199 A1 12/2008 Bar-Shalom et al. 2008/0311205 A1 12/2008 Habib et al. (75) Inventors: Peter Holm Tygesen, Smoerum (DK); 2009/0022790 A1 1/2009 Flath et al. Jan Martin Oevergaard, Frederikssund 2010/0203129 A1 8/2010 Andersen et al. (DK); Karsten Lindhardt, Haslev (DK); 2010/0204259 A1 8/2010 Tygesen et al. Louise Inoka Lyhne-versen, Gentofte 2010/0239667 A1 9/2010 Hemmingsen et al. (DK); Martin Rex Olsen, Holbaek 2010, O291205 A1 11/2010 Downie et al. (DK); Anne-Mette Haahr, Birkeroed 2011 O159100 A1 6/2011 Andersen et al. (DK); Jacob Aas Hoellund-Jensen, FOREIGN PATENT DOCUMENTS Frederikssund (DK); Pemille Kristine Hoeyrup Hemmingsen, Bagsvaerd DE 20 2006 014131 1, 2007 (DK) EP O435,726 8, 1991 EP O493513 7, 1992 EP O406315 11, 1992 (73) Assignee: Egalet Ltd., London (GB) EP 1213014 6, 2002 WO WO 89,09066 10, 1989 (*) Notice: Subject to any disclaimer, the term of this WO WO91,040 15 4f1991 patent is extended or adjusted under 35 WO WO95/22962 8, 1995 U.S.C. 154(b) by 489 days. WO WO99,51208 10, 1999 WO WOOOf 41704 T 2000 WO WO 03/024426 3, 2003 (21) Appl. No.: 12/701,429 WO WOO3,O24429 3, 2003 WO WOO3,O24430 3, 2003 (22) Filed: Feb.
    [Show full text]
  • Porphyria: a Difficult Disease to Diagnose by Marelda Abney RN
    1 Porphyria: A difficult disease to diagnose By Marelda Abney RN, BSN A Manuscript submitted in partial fulfillment ofthe requirement for the degree Master ofNursing Washington State University Intercollegiate College ofNursing Spokane, Washington July 2003 11 To the faculty ofWashington State University: The members ofthe committee appointed to examine the Intercollegiate College of Nursing research requirements and manuscript of MARELDA MARY ABNEY fmd it satisfactory and recommend that it be accepted. ,~~ 5ctl(.~~v~ Lorna Schumann, PhD, FAANP, ARNP ~~ 2u J:~ AhJ5uv Billie Severtsen, PhD, RN _~-/A~-t~£0 Sheila Masteller, MN, BSN, RN 111 Acknowledgements I would like to thank everyone who has supported me in one way or another in completing my manuscript and fulfilling my dream ofbecoming a family nurse practitioner. My deepest gratitude goes out to those who served on my committee for my clinical project. Dr. Billie Severtsen, committee member, whom I fIrst met in my undergraduate program. She was an inspiration then as she is now, in the ways ofmedical ethics and compassionate care. I have been forttmate to have had her be a part ofmy education from the beginning ofmy career through to the end ofthis project. Sheila Masteller, committee nlember and role model. I have been privileged to work with Sheila at Visiting Nurses Association where she is president and an exemplary leader in home health care. Her concern for the welfare ofpatients and staffhas made her the ideal example of leadership. Lorna Schumann, committee member and mentor. Lorna has always been there for me as I struggled down this path. She has listened when I just needed to talk which is a priceless gift.
    [Show full text]
  • American College of Epidemiology Annual Meeting Abstracts, September 7-10, 2019, Pasadena, California
    Annals of Epidemiology 36 (2019) 66e78 Contents lists available at ScienceDirect Annals of Epidemiology journal homepage: www.annalsofepidemiology.org American College of Epidemiology Annual Meeting Abstracts, September 7-10, 2019, Pasadena, California Oral Presentations Exploring uniformity of gestational diabetes Methods: We estimated the percentage of overdose deaths reported in the screening and diagnosis using real-world National Vital Statistics System with missing toxicology results from 2010- ’ electronic health record data 2016, overall and by decedents demographic and geographic characteristics. We used a multi-level model to evaluate prevalence of missingness by decedent characteristics, accounting for geographic clustering. & J.M. Lawrence, X. Li. Department of Research Evaluation, Kaiser Results: One-fifth of 351,345 drug overdose deaths from 2010-2016 did not Permanente Southern California, Pasadena, CA indicate a specific drug, declining from 24.4% in 2010 to 14.6% in 2016. In a multi-level model controlling for all predictors, deaths were less likely to Purpose: Gestational diabetes (GDM) surveillance frequently relies on In- have missing information if they occurred in metro counties compared to ternational Classification of Disease (ICD) codes to identify cases. GDM di- rural counties (aOR: 0.31, 95%CI: 0.24, 0.41) and in counties with medical agnoses can be based on several criteria including Carpenter & Coustan examiners versus coroners (aOR: 0.57, 95%CI: 0.47, 0.69). Male decedents (C&C) and International Association of Diabetes in Pregnancy Group were less likely to have missing information than females (aOR: 0.73, 95% (IADPSG). Our objectives were to describe GDM testing patterns within one CI: 0.69, 0.77), and non-Hispanic whites were more likely to have missing large health system and evaluate how well diagnostic coding corresponds information than non-Hispanic blacks (aOR: 1.31, 95%CI: 1.2, 1.4).
    [Show full text]
  • Methadone Maintenance Treatment and Its Psychosocial Effects on Individuals
    St. Catherine University SOPHIA Master of Social Work Clinical Research Papers School of Social Work 5-2014 Methadone Maintenance Treatment and its Psychosocial Effects on Individuals Fatai Adeshina Popoola St. Catherine University Follow this and additional works at: https://sophia.stkate.edu/msw_papers Part of the Social Work Commons Recommended Citation Popoola, Fatai Adeshina. (2014). Methadone Maintenance Treatment and its Psychosocial Effects on Individuals. Retrieved from Sophia, the St. Catherine University repository website: https://sophia.stkate.edu/msw_papers/378 This Clinical research paper is brought to you for free and open access by the School of Social Work at SOPHIA. It has been accepted for inclusion in Master of Social Work Clinical Research Papers by an authorized administrator of SOPHIA. For more information, please contact [email protected]. Methadone Maintenance Treatment and its Psychosocial Effects on Individuals by Fatai Adeshina Popoola (BEd\ Political Science, LADC) Proposal for a Clinical Research Paper Presented to the Faculty of the School of Social Work St. Catherine University and the University of St. Thomas St. Paul, Minnesota in Partial fulfillment of the Requirements for the Degree of Master of Social Work Committee Members Rajean P. Moone Ph.D., LNHA, (Chair) Rashad Hameed, MA, LADC Neerja Singh, Ph.D., LICSW The Clinical Research Project is a graduation requirement for MSW students at St. Catherine University/University of St. Thomas School of Social Work in St Paul, Minnesota and is conducted within a nine-month time frame to demonstrate facility with basic social research methods. Students must independently conceptualize a research problem, formulate a research design that is approved by a research committee and the university Institutional Review Board, implement the project, and publicly present the findings of the study.
    [Show full text]
  • Question of the Day Archives: Monday, December 5, 2016 Question: Calcium Oxalate Is a Widespread Toxin Found in Many Species of Plants
    Question Of the Day Archives: Monday, December 5, 2016 Question: Calcium oxalate is a widespread toxin found in many species of plants. What is the needle shaped crystal containing calcium oxalate called and what is the compilation of these structures known as? Answer: The needle shaped plant-based crystals containing calcium oxalate are known as raphides. A compilation of raphides forms the structure known as an idioblast. (Lim CS et al. Atlas of select poisonous plants and mushrooms. 2016 Disease-a-Month 62(3):37-66) Friday, December 2, 2016 Question: Which oral chelating agent has been reported to cause transient increases in plasma ALT activity in some patients as well as rare instances of mucocutaneous skin reactions? Answer: Orally administered dimercaptosuccinic acid (DMSA) has been reported to cause transient increases in ALT activity as well as rare instances of mucocutaneous skin reactions. (Bradberry S et al. Use of oral dimercaptosuccinic acid (succimer) in adult patients with inorganic lead poisoning. 2009 Q J Med 102:721-732) Thursday, December 1, 2016 Question: What is Clioquinol and why was it withdrawn from the market during the 1970s? Answer: According to the cited reference, “Between the 1950s and 1970s Clioquinol was used to treat and prevent intestinal parasitic disease [intestinal amebiasis].” “In the early 1970s Clioquinol was withdrawn from the market as an oral agent due to an association with sub-acute myelo-optic neuropathy (SMON) in Japanese patients. SMON is a syndrome that involves sensory and motor disturbances in the lower limbs as well as visual changes that are due to symmetrical demyelination of the lateral and posterior funiculi of the spinal cord, optic nerve, and peripheral nerves.
    [Show full text]
  • Levacetylmethadol
    Leflunomide/Lornoxicam 77 6. Maddison P, et al. Leflunomide in rheumatoid arthritis: recom- Levomethadone Hydrochloride (rINNM) ⊗ Lithium Salicylate mendations through a process of consensus. Rheumatology (Ox- ford) 2005; 44: 280–6. Correction. ibid.; 569. Hidrocloruro de levometadona; Levometadonhidroklorid; Lev- Lithium Salicylicum; Salicilato de litio. 7. Silverman E, et al. Long-term open-label preliminary study of ometadonhydroklorid; Levometadonihydrokloridi; Levometado- Лития Салицилат the safety and efficacy of leflunomide in patients with polyartic- no hidrochloridas; Lévométhadone, chlorhydrate de; Levometh- C H LiO = 144.1. ular-course juvenile rheumatoid arthritis. Arthritis Rheum 2005; adon-hydrochlorid; Levomethadoni hydrochloridum; (−)-Metha- 7 5 3 52: 554–62. CAS — 552-38-5. 8. Silverman E, et al. Leflunomide in Juvenile Rheumatoid Arthri- done Hydrochloride. (−)-6-Dimethylamino-4,4-diphenylheptan- tis (JRA) Investigator Group. Leflunomide or methotrexate for 3-one hydrochloride. juvenile rheumatoid arthritis. N Engl J Med 2005; 352: 1655–66. Левометадона Гидрохлорид HO Spondyloarthropathies. References to the use of leflunomide C21H27NO,HCl = 345.9. Li+ -O in ankylosing spondylitis and psoriatic arthritis (see Spondyloar- CAS — 125-58-6 (levomethadone); 5967-73-7 (levometh- thropathies, p.13). adone hydrochloride). 1. Cuchacovich M, Soto L. Leflunomide decreases joint erosions O and induces reparative changes in a patient with psoriatic arthri- tis. Ann Rheum Dis 2002; 61: 942–3. 2. Kaltwasser JP, et al. Treatment of Psoriatic Arthritis Study Profile Group. Efficacy and safety of leflunomide in the treatment of Lithium salicylate is a salicylic acid derivative (see Aspirin, psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum p.20) that has been used in rheumatic disorders, but its use cannot 2004; 50: 1939–50.
    [Show full text]
  • Supplement 1: Additional Tables and Figures
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Global Health Supplement 1: Additional tables and figures Box S1: Substances included and excluded from the International Narcotic Control Board (INCB) data on narcotic consumption, in alphabetical order. Opioids included in the opioid consumption calculation: 1. (+)-cis-3-methylfental 35. Bezitramide 2. 3-Acetylmorphine 36. Butyrfentanyl 3. 3-Methylfentanyl 37. Carfentanil 4. 3-Methylthiofentanyl 38. Carfentanyl 5. 3-Monoacetylmorphine 39. Clonitazene 6. 4-Fluoroisobutyrfentanyl 40. Codeine 7. 6-Acetylmorphine 41. Codeine-6GLUC 8. 6-Monoacetylmorphine 42. Codeine-6-glucuronide 9. Acetorphine 43. Codeine-Methyl 10. Acetyl-alpha-methylfentanyl 44. Codeine-N-oxide 11. Acetyldihydrocodeine 45. Codoxime 12. Acetylfentanyl 46. Conc. of poppy straw (C) ACA 13. Acetylmethadol 47. Conc. of poppy straw (C) AMA 14. Acetylmorphine 48. Conc. of poppy straw (C) AOA 15. Acrylfentanyl 49. Conc. of poppy straw (C) ATA 16. AH-7921 50. Conc. of poppy straw (C) GW 17. Alfentanil 51. Conc. of poppy straw (M) ACA 18. Allylprodine 52. Conc. of poppy straw (M) AMA 19. Alphacetylmethadol 53. Conc. of poppy straw (M) AOA 20. Alphameprodine 54. Conc. of poppy straw (M) ATA 21. Alphamethadol 55. Conc. of poppy straw (M) GW 22. alpha-Methylfentanyl 56. Conc. of poppy straw (N) GW 23. alpha-Methylthiofentanyl 57. Conc. of poppy straw (O) 24. Alphaprodine 58. Conc. of poppy straw (O) ACA 25. Anileridine 59. Conc. of poppy straw (O) AMA 26. Benzethidine 60. Conc. of poppy straw (O) AOA 27.
    [Show full text]
  • Alcohol and Drug Abuse Subchapter 9
    Chapter 8 – Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority This rule is established under the authority of 18 V.S.A. §§ 4201 and 4202 which authorizes the Vermont Board of Health to designate regulated drugs for the protection of public health and safety. 2.0 Purpose This rule designates drugs and other chemical substances that are illegal or judged to be potentially fatal or harmful for human consumption unless prescribed and dispensed by a professional licensed to prescribe or dispense them and used in accordance with the prescription. The rule restricts the possession of certain drugs above a specified quantity. The rule also establishes benchmark unlawful dosages for certain drugs to provide a baseline for use by prosecutors to seek enhanced penalties for possession of higher quantities of the drug in accordance with multipliers found at 18 V.S.A. § 4234. 3.0 Definitions 3.1 “Analog” means one of a group of chemical components similar in structure but different with respect to elemental composition. It can differ in one or more atoms, functional groups or substructures, which are replaced with other atoms, groups or substructures. 3.2 “Benchmark Unlawful Dosage” means the quantity of a drug commonly consumed over a twenty-four-hour period for any therapeutic purpose, as established by the manufacturer of the drug. Benchmark Unlawful dosage is not a medical or pharmacologic concept with any implication for medical practice. Instead, it is a legal concept established only for the purpose of calculating penalties for improper sale, possession, or dispensing of drugs pursuant to 18 V.S.A.
    [Show full text]
  • Pharmacogenomic Study of Opioid Addicts in Methadone Treatment
    Pharmacogenomic study of opioid addicts in methadone treatment PhD candidate: Francina Fonseca Casals Doctoral thesis Universitat Pompeu Fabra / 2010 PhD directors: Dr. Rafael de la Torre i Fornell (CEXS, Universitat Pompeu Fabra) Dra. Marta Torrens Mèlich (Departament de Psiquiatria, Universitat Autònoma de Barcelona) “It's not the mountain we conquer, but ourselves" Sir Edmund Percival Hillary iii AGRAÏMENTS De tots aquests anys treballant en aquest projecte, el més essencial ha estat aprendre la importància del treball en equip; els resultats que es detallaran són fruit de l’esforç de moltes persones. En primer lloc, agrair la col·laboració dels pacients del CAS Barceloneta que han participat a l’estudi; sense ells, no hagués estat possible. Vull agrair també la implicació de l’equip d’infermeria del CAS Barceloneta i el seu suport desinteressat en la recollida de mostres. A la Laura Díaz, per l’ajuda amb les entrevistes. A l’equip del CRG: en Rafa De Cid, la Mònica Gratacòs i el Xavier Estivill per tota la feina en l’anàlisi genètica. L’equip de Farmacologia de l’IMIM, en Toni Pastor, l’Elisabet Cuyàs i molt especialment a la Neus Pizarro que va tenir la paciència d’explicar-me tot el procés d’anàlisi de les mostres. L’Esther Español que ha editat el document i la Carla Astals pel disseny de la coberta. A l’Institut Municipal d’Investigació Mèdica (IMIM), per l’ajut rebut pel pagament de les despeses finals d’enquadernació de la tesi. La Rocío Martín-Santos i en Magí Farré, pel seu recolzament constant i les idees brillants quan ens encallàvem.
    [Show full text]